NCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
9 trialsNCT05059522 2025-06-25
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
Phase 3 Active not recruiting
NCT05071937 2025-06-22
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT04703920 2025-01-23
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT04672460 2024-09-25
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT04598321 2023-10-12
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Brown University
Phase 1 Terminated
NCT03642132 2023-04-06
JAVELIN OVARIAN PARP100
Pfizer
Phase 3 Terminated
NCT02836028 2018-09-18
A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Pfizer
Phase 2 Withdrawn
NCT02567396 2017-04-24
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn